Abstract:Background: Cancer-associated fibroblasts (CAFs) in pancreatic adenocarcinoma (PDAC) are known to play a significant role in regulating tumor progression, invasion, and metastasis. Multiple studies using experimental strategies, as well as single-cell RNA-sequencing (scRNAseq) technology, have shown the existence of subpopulations of PDAC CAF cells, with divergent physical and biological characteristics. However, how to translate CAF cell subpopulations to the clinic remains unclear. Methods: We developed a computational method for scRNAseq, SCISSORS, to identify rare cell clusters and determine exemplar genes. Using SCISSORS, we have defined human exemplar genes of the previously described myCAF and iCAF cell subpopulations using scRNAseq data. These exemplar genes were then used to develop a single-sample classifier (SSC) for PDAC CAFs that we call CAPER in bulk RNAseq data. CAPER was trained using penalized logistic regression in 4 datasets (n= 372) and validated in 8 datasets (n= 593). Results: SCISSORS was able to identify rare cells such as previously described apCAFs (0.59% of cells) and basal-like cell clusters (0.092% of cells) that were missed in the previous analysis. We hypothesized that the sensitivity of SCISSORS would allow us to define exemplar genes that may be applied to bulkRNAseq. Indeed, the top ranked 25 exemplar genes defined by SCISSORS were associated with overall survival (OS) (10 datasets, n=948, p=0.017, log-rank test). To develop a clinically usable classifier, we used the SCISSORS exemplar genes to develop the SSC CAPER which consists of 9 gene pairs. CAPER CAF calls in the validation datasets showed high reproducibility compared with cluster-based labels (AUC: 0.956). In a meta-analysis, patients with CAPER myCAF subtypes showed shorter OS (median OS: 18.0m) compared to CAPER iCAF subtypes (median OS: 28.7m) (p<0.001, log-rank test). Multivariable analysis found that CAPER CAF subtypes were independently prognostic when included with PurIST tumor subtype calls (CAPER p<0.001, PurIST p<0.001, Cox regression). Interestingly, patients subtyped as basal-like for the tumor and myCAF for the CAF showed the worst outcome with a median OS of 11.2 months; while patients subtyped as classical for the tumor and iCAF for the CAF showed the best outcome with a median OS of 30.2 months (p<0.001, log-rank test). Conclusions: CAF genes have largely been evaluated in scRNAseq. We have defined CAF exemplar genes that can be applied to bulk RNAseq, and have developed a clinically usable classifier similar to the now CLIA-approved PurIST that we call CAPER that is robust and accurate for the classification of CAF subtypes in patients. The ability to evaluate CAF subtypes in bulk gene expression provides a powerful tool that may be applied to the plethora of data from patients and clinical trials. CAF subtypes are independently prognostic compared to tumor-intrinsic subtypes, supporting important biological implications, and may facilitate the design of future clinical trials. Citation Format: Xianlu L. Peng, Elena Kharitonova, Joseph Kearney, Ian McCabe, Madison Jenner, Ashley B. Morrison, Alina Iuga, Naim U. Rashid, Jen Jen Yeh. Clinically usable classification of cancer-associated fibroblast subtypes in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr C015.

PurIST Pancreatic Cancer Classifier: Analytic Validation of a 16-RNA Expression Signature Distinguishing Basal and Classical Subtypes

Abstract C109: Nanostring-based subtyping of pancreatic ductal adenocarcinoma is strongly influenced by the stromal compartment

Abstract 2542: Real-world validation of the PurIST classifier demonstrates enhanced therapy selection for pancreatic ductal adenocarcinoma (PDAC) patients

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy

Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics

Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer

Spatially-resolved single-cell assessment of pancreatic cancer expression subtypes reveals co-expressor phenotypes and extensive intra-tumoral heterogeneity

Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell‐free RNA

A novel prostate cancer subtyping classifier based on luminal and basal phenotypes

Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)

Transcriptional deconvolution reveals consistent functional subtypes of pancreatic cancer epithelium and stroma

Abstract B110: Molecular subtypes from endoscopy ultrasound-guided biopsy samples collected at initial diagnosis predict therapeutic response to neoadjuvant chemotherapy in pancreatic cancer

Revealing Platelet-Related Subtypes and Prognostic Signature in Pancreatic Adenocarcinoma

Abstract A067: A single sample classifier of Bailey's molecular subtype of PDAC

Abstract C015: Clinically usable classification of cancer-associated fibroblast subtypes in pancreatic cancer

Abstract B066: Keratin 17 and GATA6 expression in pancreatic ductal adenocarcinoma: A subtyping stratification approach

Clinical Impact of Molecular Subtyping of Pancreatic Cancer

KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping

Tumor-intrinsic and Cancer-associated Fibroblast Subtypes Independently Predict Outcomes in Pancreatic Cancer

Molecular Subtypes of Pancreatic Cancer: A Proteomics Approach